Lura Morris

Phase I Interim Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory (R/R) Multiple Myeloma (MM)

M. Amiot, R. Vij, Shaji K. Kumar, 2015 .

A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma.

E. Arriola, J. Ross, M. Mateos, 2021, Clinical lymphoma, myeloma & leukemia.

Phase 1b interim results: Venetoclax (ABT-199/GDC-0199) in combination with bortezomib (BTZ) and dexamethasone (Dex) in relapsed/refractory (R/R) multiple myeloma (MM).

A. Chanan-Khan, A. Roberts, P. Moreau, 2015 .

Phase I interim safety and efficacy of venetoclax (ABT-199/GDC-0199) monotherapy for relapsed/refractory (R/R) multiple myeloma (MM).

M. Amiot, R. Vij, Shaji K. Kumar, 2015 .

Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 1b Results

A. Chanan-Khan, Shaji K. Kumar, A. Roberts, 2015 .